Stockscreener 앱 받기
1.25
4.17%
0.05
시간 외 거래:
1.24
-0.01
-0.80%
전일 마감가:
$1.20
열려 있는:
$1.22
하루 거래량:
1.39M
Relative Volume:
1.17
시가총액:
$311.62M
수익:
$14.78M
순이익/손실:
$-64.01M
주가수익비율:
-4.3509
EPS:
-0.2873
순현금흐름:
$-22.59M
1주 성능:
+1.63%
1개월 성능:
+0.00%
6개월 성능:
-29.38%
1년 성능:
+45.62%
1일 변동 폭
$1.22
$1.27
1주일 범위
$1.20
$1.3179
52주 변동 폭
$0.829
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.25 | 306.64M | 14.78M | -64.01M | -22.59M | -0.2873 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit - Traders Union
Lineage Cell Shareholders Reaffirm Governance and Executive Pay - TipRanks
Lineage Cell (NYSE: LCTX) investors back board, say-on-pay as OPC1 grant bid withdrawn - Stock Titan
LCTX Q1 2026 Earnings: EPS Miss Reflects Ongoing R&D InvestmentTrough Earnings Signal - newsline.com
LCTX Q1 2026 Earnings: EPS Misses Estimates by 47% as Company Continues Clinical DevelopmentReturn On Assets - newsline.com
How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets - Yahoo Finance
LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61 - MSN
LCTX Q1 2026 Earnings: Wider Loss Than Expected Amid Ongoing Pipeline DevelopmentForward EPS Estimate - newsline.com
LCTX Q1 2026 Earnings: Missed Estimates as R&D Spending Weighs on Bottom LineHealthcare Earnings Report - The Legal Advocate
Lineage Cell Therapeutics (LCTX) Gains 3% as Biotech Sector Finds SupportNHNL Ratio - The Legal Advocate
Lineage Cell Therapeutics Inc. (LCTX) Q1 2026 Earnings: EPS Misses Estimates Amid Pipeline Progress, Stock Rises 3.08%Annual Earnings Summary - The Legal Advocate
Lineage Cell Therapeutics spotlights CEO participation in fireside chat with HCWCO at BioConnect - Traders Union
Lineage Cell Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Continues Pipeline InvestmentEstimate Accuracy - newsline.com
Promising Penny Stocks To Consider In May 2026 - simplywall.st
Lineage Cell Therapeutics Inc. (LCTX) Q1 2026 Earnings: Miss on EPS as Clinical-Stage Biotech Continues DevelopmentROA Comparison - newsline.com
Lineage Cell Therapeutics (LCTX) Slides 1.52% – Testing Key Support Near $1.23Fear Greed Extreme - newsline.com
LCTX Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Reports No Revenue - The Legal Advocate
Lineage reports positive 36-month findings on GA cell therapy - Eyes On Eyecare
Earnings Preview: LCTX to Report Financial Results Post-market on May 12 - Moomoo
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Investing News Network
Lineage Cell Therapeutics, Inc. Common Stock (NY: LCTX - FinancialContent
Lineage Cell Therapeutics, Inc. Common Stock (NYSE:LCTX) Stock Quote - FinancialContent
Lineage Cell Therapeutics Q1 Earnings Call Highlights - sharewise.com
Lineage Cell Therapeutics Q1 2026 earnings preview - MSN
Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies - Traders Union
Lineage Cell Therapeutics (LCTX) Returns To Loss In Q1 2026 Challenging Profitability Narratives - Sahm
Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses - TipRanks
Q1 2026 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call Transcript - Insider Monkey
Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing - MSN
Lineage Cell (LCTX) reports Q1 loss, lags revenue estimates - MSN
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Lineage Cell Therapeutics (LCTX) Reports Q1 2026 Earnings and St - GuruFocus
TradingKey - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highl - GuruFocus
Lineage Cell Therapeutics (LCTX) Reports Q1 Results and Advancem - GuruFocus
Is Lineage Cell Therapeutics (LCTX) Overvalued After Q1 2026 EPS - GuruFocus
Lineage Cell (LCTX) Receives Funding to Support Operations Throu - GuruFocus
LCTX: Pipeline expansion, manufacturing progress, and strong cash runway drive 2026 outlook - TradingView
LCTX: Strong pipeline expansion and robust cash position support continued clinical and manufacturing progress - TradingView
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):